Month: November 2021

Nov 17 2021

Uncategorized

ORYZON enrolls first patient in EVOLUTION, a Phase IIb clinical trial with vafidemstat in schizophrenia

by Clinical Editor

No Comments

Primary objectives: to assess the effect of vafidemstat to address negative and cognitive symptoms in schizophrenia Phase IIb adaptive trial planning to enroll 100 patients Second Phase IIb study of...

Nov 17 2021

Uncategorized

Parents of accused killer struggled to help him with schizophrenia diagnosis

by Clinical Editor

No Comments

Linda Frederick, 64, was a devoted mother to two children, says her longtime friend. On Sunday night, her son allegedly stabbed her to death inside her home.

Nov 16 2021

Uncategorized

Managing Agitation in Schizophrenia and Bipolar Disorder

by Clinical Editor

No Comments

For patients with schizophrenia and bipolar disorder who exhibit agitation, suboptimal treatments have been overused while better-tolerated and possibly more-effective interventions have been …

Nov 16 2021

Uncategorized

Schizophrenia: A Difference of Kind

by Clinical Editor

No Comments

I wish here to provide a brief refutation of this notion and an examination of schizophrenia as a pathology that differs in kind from normal human experience. For these and...

Nov 16 2021

Uncategorized

Video: Incredible bond between uncle with schizophrenia and his one-year-old nephew

by Clinical Editor

No Comments

When his mental health problems started to get worse, Alexander ‘Adder’ Shepherd, 32, sadly lost a lot of his friends, his family said. But it was love at first sight...

Nov 16 2021

Uncategorized

Schizophrenia drug landscape: a stagnant field on the cusp of change?

by Clinical Editor

No Comments

Several pipeline therapies could shake up the schizophrenia field, but their road through development is unlikely to be an easy path. Most new drugs in schizophrenia have relied on similar...

Nov 16 2021

Uncategorized

Antipsychotics and New-Onset Obsessive-Compulsive Disorder in Schizophrenia

by Clinical Editor

No Comments

Comorbidity or medication adverse effect? Researchers performed a nested case-control study of new-onset obsessive-compulsive disorder following antipsychotic use in schizophrenia.

Nov 15 2021

Uncategorized

Schizophrenia: A Difference of Kind

by Clinical Editor

No Comments

I wish here to provide a brief refutation of this notion and an examination of schizophrenia as a pathology that differs in kind from normal human experience. For these and...

Nov 15 2021

Uncategorized

Antipsychotics and New-Onset Obsessive-Compulsive Disorder in Schizophrenia

by Clinical Editor

No Comments

Comorbidity or medication adverse effect? Researchers performed a nested case-control study of new-onset obsessive-compulsive disorder following antipsychotic use in schizophrenia.

Nov 15 2021

Uncategorized

Schizophrenia drug landscape: a stagnant field on the cusp of change?

by Clinical Editor

No Comments

Several pipeline therapies could shake up the schizophrenia field, but their road through development is unlikely to be an easy path. Most new drugs in schizophrenia have relied on similar...